Stock Screener App

Frei -

Installieren

3.10

54.23% 1.09

after-market

Handel nachbörslich: 3.11 0.010 +0.32%

Tvardi Therapeutics Inc (TVRD)

Überblick Nachrichten Preisverlauf Forum Prognose

Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten

Tvardi Therapeutics (TVRD) Study result Summary - Quartr

Why Tvardi Therapeutics (TVRD) Stock Is Up Today - Quiver Quantitative

TVRD Reiterated by BTIG -- Price Target Maintained at $15.00 - GuruFocus

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) stock jumps as Phase 1 data puts cash-value biotech under heavy churn - TechStock²

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109 - Investorideas.com

With tardy Tvardi phase I win, skin in STAT3 game plus GI - BioWorld News

Tvardi reports 60% immune cell reductions - grafa.com

Tvardi Therapeutics Announces Phase 1 Results For TTI-109 And Plans Advancement Into Dermatologic And Gastrointestinal Diseases - marketscreener.com

Tvardi reports phase 1 results for STAT3 inhibitor TTI-109 - Investing.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109 - TipRanks

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement - The Manila Times

Tvardi Therapeutics reports Phase 1 TTI-109 data showing bioequivalence to TTI-101, improved tolerability - TradingView

Tvardi Therapeutics (NASDAQ: TVRD) unveils Phase 1 TTI-109 data and plans Phase 2 trials - Stock Titan

Tvardi says TTI-109 matched exposure, cut diarrhea in phase 1 - Stock Titan

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Tvardi Therapeutics Inc. Actuals & Estimates (NASDAQ:TVRD) - TradingView

Price to book forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView

Enterprise value to EBIT forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView

Enterprise value to revenue forward of Tvardi Therapeutics Inc. – MUN:69C - TradingView

Price to earnings forward of Tvardi Therapeutics Inc. – MUN:69C - TradingView

Tvardi Therapeutics Inc. Actuals & Estimates (LSE:0HTC) - TradingView

Price to earnings forward of Tvardi Therapeutics Inc. – LSE:0HTC - TradingView

TVRD Forecast — Price Target — Prediction for 2027 - TradingView

Enterprise value to EBITDA forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView

H.C. Wainwright Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo

SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView

Price to sales forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView

Price to sales forward of Tvardi Therapeutics Inc. – LSE:0HTC - TradingView

TVRD PE Ratio & Valuation, Is TVRD Overvalued - Intellectia AI

Tvardi Therapeutics Ord Shs (TVRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Tvardi Therapeutics Ord Shs (TVRD) Institutional Confidence - TradingKey

Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Tvardi Therapeutics (TVRD) Slides as Stock Approaches Key Support Near $2.51Growth ETF - newsline.com

TVRD Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Pipeline ProgressEstimate Dispersion - newsline.com

Tvardi Therapeutics Shareholders Approve Directors and Governance Measures - The Globe and Mail

Tvardi Therapeutics Inc. (TVRD) Q1 2026 Earnings: Beats EPS Estimates Amid Continued R&D Progress - newsline.com

Tvardi Therapeutics (TVRD) grants 6,000 stock options to director - Stock Titan

Tvardi Therapeutics (TVRD) director granted 6,000 options at $2.78 exercise price - Stock Titan

Tvardi Therapeutics (TVRD) director Sujal Shah awarded 6,000 stock options at $2.78 - Stock Titan

Tvardi Therapeutics (TVRD) director receives grant of 6,000 stock options at $2.78 - Stock Titan

Tvardi Therapeutics (TVRD) director awarded 6,000 stock options at $2.78 - Stock Titan

Tvardi Therapeutics (TVRD) investors approve directors, say-on-pay and Deloitte as 2026 auditor - Stock Titan

Tvardi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shiff Susan Ph.D. - Moomoo

Tvardi Therapeutics (TVRD) Declines 2.88% as Stock Tests Key Support; Near-Term Outlook Hinges on $2.56 FloorFactor Momentum - newsline.com

Tvardi Therapeutics (TVRD) Dips 2.88% as Shares Test Near-Term SupportLeading Diagonal - dars.gov.et

This Cerebras Systems analyst begins coverage on a bullish note; here are top 3 initiations for Monday - MSN

H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating By Investing.com - Investing.com South Africa

H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating - Investing.com

HC Wainwright Initiates Tvardi Therapeutics at Buy With $9 Price Target - Moomoo

H.C. Wainwright Initiates Tvardi Therapeutics(TVRD.US) With Buy Rating, Announces Target Price $9 - Moomoo

Tvardi Therapeutics: STAT3 inhibitor TTI-109 aims to address fibrosis and immune disorders, with key data expected soon - TradingView

Tvardi Therapeutics: STAT3 inhibitor programs advance with new data expected, targeting fibrosis and immune disorders - TradingView

MSN Money - MSN

TVRD Q1 2026 Earnings: Net Loss Narrows as Clinical Pipeline AdvancesEarnings Beat Streak - newsline.com

Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN

Tvardi Therapeutics (TVRD) Declines 4%: Support at $3.18 in FocusVWAP Deviation - newsline.com

TVRDTvardi Therapeutics Inc Stock Price and Quote - Finviz

Tvardi Therapeutics (TVRD) Holds Steady Near Support Amid Low-Volume TradingShort Setup Alerts - The Legal Advocate

Tvardi Therapeutics Q1 2026 Earnings: Narrower-than-expected loss as pipeline advancesEarnings Manipulation Risk - Newser

INSM

$112.84

1.17%

RPRX

$57.80

1.55%

ROIV

$36.31

2.60%

MRNA

$79.77

2.48%

ONC

$308.96

0.16%

RVMD

$190.46

0.25%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters